Jason P. Rhodes - 04 Oct 2021 Form 4 Insider Report for Gemini Therapeutics, Inc. /DE (IRON)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: IRON
Reported as of: 04 Oct 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Oct 2021, 16:15:39 UTC
Prior SEC filing: 29 Sep 2021
Next SEC filing: 05 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Jason Meyenburg, attorney-in-fact

Key filing fact

Jason P. Rhodes filed Form 4 for Gemini Therapeutics, Inc. /DE (IRON) on 06 Oct 2021.

Key facts

This page summarizes Jason P. Rhodes's Form 4 filing for Gemini Therapeutics, Inc. /DE (IRON).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Oct 2021, 16:15.

Change

Previous filing in this sequence was filed on 29 Sep 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IRON transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +17,245
Change %
Price: $0.000000
Shares after: 17,245
Date: 04 Oct 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,245
Exercise price: $3.80
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.

Footnote F2

This option was granted to the Reporting Person, a director of the Issuer and a member of Atlas Venture Life Science Advisors, LLC ("Atlas"). The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.